Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Corton Capital Inc.

Corton Capital Inc. lowered its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK) by 61.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,759 shares of the company’s stock after selling 9,075 shares during the period. Corton Capital Inc.’s holdings in Scholar Rock were worth $249,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the company. FMR LLC grew its position in shares of Scholar Rock by 33.7% in the fourth quarter. FMR LLC now owns 13,635,261 shares of the company’s stock valued at $589,316,000 after purchasing an additional 3,439,215 shares during the last quarter. Marshall Wace LLP grew its holdings in Scholar Rock by 1,283.7% during the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company’s stock valued at $127,301,000 after buying an additional 2,732,546 shares during the last quarter. Norges Bank purchased a new position in Scholar Rock during the fourth quarter worth $86,043,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Scholar Rock in the fourth quarter worth $68,930,000. Finally, Wellington Management Group LLP lifted its position in shares of Scholar Rock by 763.8% in the fourth quarter. Wellington Management Group LLP now owns 1,725,622 shares of the company’s stock valued at $74,581,000 after acquiring an additional 1,525,845 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK opened at $29.70 on Thursday. The firm has a market capitalization of $2.82 billion, a PE ratio of -12.64 and a beta of 0.37. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The business has a 50-day moving average of $31.86 and a two-hundred day moving average of $35.80.

Insider Buying and Selling

In related news, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction on Monday, March 17th. The shares were sold at an average price of $34.42, for a total transaction of $34,626.52. Following the transaction, the director now owns 30,319 shares in the company, valued at approximately $1,043,579.98. The trade was a 3.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Tracey Sacco sold 5,000 shares of the firm’s stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $32.83, for a total value of $164,150.00. Following the completion of the transaction, the insider now directly owns 71,750 shares in the company, valued at $2,355,552.50. This trade represents a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 255,231 shares of company stock valued at $9,220,236. 13.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Wedbush restated an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and an average price target of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.